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Vitamin D analogues with reduced hypercalcemic activity are under clinical investigation for use against colon cancer and other
neoplasias. However, only a subset of patients responds to this therapy, most probably due to loss of vitamin D receptor (VDR)
expression during tumour progression. Recent data show that SNAIL transcription factor represses VDR expression, and thus
abolishes the antiproliferative and prodifferentiation effects of VDR ligands in cultured cancer cells and their antitumour action in
xenografted mice. Accordingly, upregulation of SNAIL in human colon tumours associates with downregulation of VDR. These findings
suggest that SNAIL may be associated with loss of responsiveness to vitamin D analogues and may thus be used as an indicator of
patients who are unlikely to respond to this therapy.
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Colorectal cancer is the most frequent neoplasia and the second
leading cause of cancer death in Europe, with 218000 new cases
diagnosed each year and an overall rate of 58.1 cases per 100000
person-years (Ferlay et al, 1999). By sex, it constitutes the second
most frequent tumour in women after breast cancer and the third
in men after lung and prostate tumours. Surgical resection is the
therapy of choice for localised tumours, which is curative at an
early stage of the disease. However, there is no satisfactory
treatment for advanced colon cancer despite the improvement in
systemic therapy and radiotherapy in the last decades.
Vitamin D intake and sunlight exposure show a protective effect
against colorectal carcinogenesis (Peters et al, 2001, and refs.
therein). A recent study suggests that vitamin D and calcium
supplementation act together to reduce colorectal adenoma risk
(Grau et al, 2003). In line with epidemiological data, 1a,25-
dihydroxyvitamin D3 (1,25(OH)2D3, Calcitriol), the most active
metabolite of vitamin D, has antiproliferative, proapoptotic and
prodifferentiation effects on many tumour cells in vitro (Figure 1),
including cells of the large intestine, in addition to its classical role
regulating calcium and phosphate homeostasis and bone biology
(Hansen et al, 2001; Lamprecht and Lipkin, 2003). Remarkably,
some vitamin D analogues enhance the cytotoxic effects of
chemotherapeutic drugs and radiotherapy.
The clinical use of 1,25(OH)2D3 is hampered by its hypercalce-
mic effect. For this reason, a number of 1,25(OH)2D3 analogues
(deltanoids) with variable biological activity and reduced calcemic
properties have been synthesised (Carlberg and Mourin ˜o, 2003).
Several of them show promising anticancer action in preclinical
studies and are currently in clinical trials (Hansen et al, 2001). The
use of vitamin D analogues for prevention or therapy in cancer
patients is still in its infancy. Few Phase I and II studies have been
reported, in general showing acceptable toxicity but activity only
in a subset of patients.
1,25(OH)2D3 synthesis and action
Dietary vitamin D is scarce, and most vitamin D3 is synthesised in
the skin by the action of sunlight. Ultraviolet-B radiation converts
7-dehydrocholesterol to previtamin D3, which thermoisomerises to
vitamin D3. This is subjected to two consecutive hydroxylation
reactions: first in the liver by vitamin D3 25-hydroxylase
(CYP27A1) and then in the kidney by 25-hydroxyvitamin D3-1a-
hydroxylase (CYP27B1) to render 1,25(OH)2D3. Recently, 25-
hydroxyvitamin D3-1a-hydroxylase has also been found to be
expressed by osteoblasts, keratinocytes, chondrocytes, macro-
phages and several epithelia including the intestinal (MacDonald
et al, 2001). 1,25(OH)2D3 is converted to the much less active
1,24,25(OH)3D3 compound by the 24-hydroxylase (CYP24) (Mac-
Donald et al, 2001).
Vitamin D receptor (VDR) is a ligand-regulated transcription
factor that mediates most, if not all, the biological effects of
1,25(OH)2D3 (MacDonald et al, 2001). Most 1,25(OH)2D3 analo-
gues act also via VDR, although some have effects unrelated to
VDR binding such as CYP24 enzyme inhibition (Posner et al,
2004). For years considered to be exclusively nuclear, VDR is now
believed to shuttle constantly between nucleus and cytoplasm;
ligand binding and its interaction with the retinoid X receptor
(RXR) increase nuclear accumulation (Pru ¨fer and Barsony, 2002).
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SMRT, N-CoR or Alien, actively repressing target genes. Hormone
binding induces a conformational change in VDR that increases
the formation of VDR-RXR heterodimers and DNA binding, and
causes corepressor release. Subsequently, VDR binds coactivators
(SRC-1, ACTR, GRIP-1 and SKIP, among others) and interacts
with the multiprotein DRIP (vitamin-D-receptor-interacting pro-
tein) and chromatin remodeller complexes, which finally leads to
activation of genes mediating most hormone actions (MacDonald
et al, 2001). Furthermore, VDR is phosphorylated at several
residues by different kinases, which contribute to the regulation of
its localisation and function in ways that remain to be understood.
In addition to the genomic pathway involving nuclear VDR, a
nongenomic pathway of 1,25(OH)2D3 action has been postulated
(Figure 1). This latter pathway is characterised by rapid, gene
expression-independent effects such as changes in ion levels or the
activity of some kinases, which might be mediated by membrane
or cytosolic VDR or by other unknown receptors (Lamprecht and
Lipkin, 2003, and references therein).
1,25(OH)2D3 and colon cancer
The predominant effect of 1,25(OH)2D3, be it antiproliferative,
proapoptotic or prodifferentiation, depends on the cell type, and is
supposedly based on the set of genes regulated in each particular
system. Cell-cycle arrest may result from the induction of cyclin-
dependent kinase inhibitors such as p21
CIP and p27
KIP and the
repression of cyclin D1, whereas the activation of BAX and BAK
and the inhibition of BCL2 and IAP contribute to apoptotic
induction (Figure 1) (Lamprecht and Lipkin, 2003).
Mutation of APC (adenomatous polyposis coli) tumour suppres-
sor gene or, less frequently, of CTNNB1 encoding b-catenin, a
component of adherens junctions involved in intercellular adhe-
sion, is a common early alteration in human colon cancer (Giles
et al, 2003). These mutations, or stimulation of the signaling
pathway by Wnt extracellular factors, prevent b-catenin protein
degradation by a complex involving APC, Axin and the protein
kinases GSK-3b and CKIa, causing its accumulation in the cytosol
and translocation into the nucleus (Giles et al, 2003). In the
nucleus, b-catenin forms complexes with the TCF/LEF family of
transcriptional regulators leading to the activation of genes
involved in proliferation and invasiveness, thus promoting colon
cancer progression (Giles et al, 2003 and references therein).
A study by our group has revealed that 1,25(OH)2D3 and several
nonhypercalcemic analogues promote the differentiation and
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Figure 1 Effects of 1,25(OH)2D3 in colon cancer cells. SNAIL inhibits
1,25(OH)2D3 action by repressing VDR gene expression. Discontinuous
lanes refer to not confirmed processes. 1,25(OH)2D3 inhibits b-catenin
signalling (Pa ´lmer et al, 2001) and up- or down-regulates numerous genes,
directly or indirectly (Lamprecht and Lipkin, 2003; Pa ´lmer et al, 2003).
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Figure 2 Opposite pattern of expression of VDR and SNAIL during human colon cancer progression. As indicated, downregulation of VDR has been found
in some studies only in high-grade carcinomas, whereas in other studies it is observed already in low- and intermediate-grade tumours. These data indicate
that the efficacy of therapy with 1,25(OH)2D3 analogues is lost at late steps of tumour progression.
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high VDR levels (SW480-ADH) through the induction of E-
cadherin and other adhesion proteins and the blockade of b-
catenin transcriptional activity (Pa ´lmer et al, 2001) (Figure 1). As a
result, 1,25(OH)2D3 inhibits the expression of b-catenin target
genes such as c-MYC, TCF1 or CD44 (Pa ´lmer et al, 2001). In total,
200 1,25(OH)2D3 target genes have been reported in SW480-ADH
cells: they are involved in different aspects of cell biology and
support the beneficial effect of the hormone on cell phenotype and
growth (Pa ´lmer et al, 2003). In summary, 1,25(OH)2D3 regulates
many genes either directly, through VDR binding to their
regulatory regions, or indirectly, via intermediate genes or by
affecting other pathways, such as Wnt/b-catenin, that are related to
its antitumoral action.
VDR and colon cancer
In the human colon, normal epithelial cells and some cancer cells
express VDR (Ka ´llay et al, 2002). Furthermore, some colon cancer
cells express 25-hydroxyvitamin D3-1a-hydroxylase and can thus
synthesise 1,25(OH)2D3 from its precursor (Cross et al, 2001). This
suggests that the VDR expression observed in low-grade tumours
and the tumour-localised production of this hormone could be an
autocrine/paracrine means to control tumour progression. Con-
cordantly, a high level of VDR expression is associated with a
favourable prognosis in colorectal cancer (Cross et al, 1996; Evans
et al, 1998). Vitamin D receptor expression is enhanced during
early stages of colon cancer but, analogously to oestrogen and
progesterone receptors in breast cancer, it is downregulated during
late colon cancer progression (Sheinin et al, 2000; Cross et al,
2001), causing ligand unresponsiveness and, possibly, failure of
therapy with vitamin D analogues (Figure 2). Some studies indicate
that VDR expression decreases in high-grade carcinomas to levels
found in normal mucosa (Sheinin et al, 2000; Cross et al, 2001;
Ka ´llay et al, 2002), while others found diminished VDR expression
already in low- and intermediate-grade tumours and a decrease
below normal mucosa levels in high-grade carcinomas (Pa ´lmer
et al, 2004) (Figure 2).
These data suggest that VDR-deficient mice (whose phenotype
closely resembles that of human with vitamin D-dependent rickets
type II) may be prone to develop colon cancer. However, these
animals display hyperproliferation and oxidative stress in the
distal colon, but not elevated rates of spontaneous colon cancer
(Ka ´llay et al, 2001). Likewise, mice lacking 25-hydroxyvitamin D3-
1a-hydroxylase show similar abnormalities to humans with
vitamin D-dependent rickets type I, while no changes in intestines
or tumour development have been reported (Bikle et al, 2004).
Several VDR polymorphisms have been described. However,
most VDR polymorphisms do not result in structural alteration in
the VDR protein and are of unknown functional significance and
unrelated to adenoma recurrence, and furthermore do not modify
the associations with vitamin D or calcium (Peters et al, 2001; Grau
et al, 2003; Sutton and MacDonald, 2003; Harris and Go, 2004).
SNAIL: biological effects and regulation
SNAIL is a zinc-finger transcription factor expressed in migratory
processes during embryonic development that has recently been
implicated in cancer (Nieto, 2002). SNAIL upregulation in
epithelial cells induces the acquisition of cell movement and
invasiveness, at least in part due to the repression of E-cadherin
expression (Batlle et al, 2000; Cano et al, 2000). In the E-cadherin
gene promoter, SNAIL binds to regions that contain the consensus
core sequence (CAGGTC), a motif that is a subset of the E-box
(CANNTG), the conserved binding site of basic helix-loop-helix
transcription factors. The acquisition of the invasive phenotype is
linked to SNAIL upregulation and concomitant E-cadherin
repression in gastric, melanoma, breast and hepatocellular cancer
cells. Either directly or indirectly, SNAIL also downregulates other
genes encoding adhesion proteins such as several claudins,
occludin and ZO-1, and also those for MUC-1 and aromatase,
while it upregulates several metalloproteinases in different cell
types. Additionally, SNAIL attenuates cell proliferation and confers
resistance to apoptosis in breast cancer cells (Vega et al, 2004).
Supporting a role of SNAIL in colon tumorigenesis, down-
regulation of SNAIL suppresses both total tumour number and
incidence of large tumours in APC
min mice (Roy et al, 2004).
Studies performed with human and murine SNAIL gene promoters
have evidenced the dependence of the transcription of this gene on
the activity of signalling pathways involving MEK1/2, PI3K/Akt
and NFkB/p65 (Peinado et al, 2003; Barbera ´ et al, 2004). In
mammary epithelial cells, SNAIL is repressed by MTA-3, a gene
induced by oestrogen.
Relation between SNAIL and VDR expression
Our group observed that in a panel of human colon cancer cell
lines, high SNAIL expression associates with undifferentiation and
low VDR and E-cadherin expression, and vice versa. Subsequent
work revealed that SNAIL protein binds to and represses (50%) the
human VDR gene promoter (Pa ´lmer et al, 2004). As a result,
SNAIL abolishes the induction by 1,25(OH)2D3 of E-cadherin and
other target genes (Figure 1). Moreover, SNAIL-overexpressing
human colon cancer cells became resistant to growth inhibition by
the vitamin D analogue EB1089 when they were injected
subcutaneously in immune-deficient mice. In humans, we have
found increased SNAIL RNA expression in tumour vs normal
tissue (22 out of 32 patients), and a significant inverse correlation
between the expression of SNAIL and that of VDR and E-cadherin
(Pa ´lmer et al, 2004). A later study of a larger series of patients
confirmed this relation, and showed that loss of VDR RNA is
linked to poor differentiation (F Bonilla, personal communica-
tion). These data indicate that the loss of VDR RNA expression
during colon cancer progression is probably related to SNAIL
upregulation, and therefore that high levels of SNAIL may be
responsible for the failure of therapy with vitamin D analogues in
patients with this and perhaps other neoplasias (Figure 2). In
contrast to our data, SNAIL RNA expression was only detected in a
low proportion of human colon tumours in another study
(Rosivatz et al, 2004). The reasons for this discrepancy are unclear.
Loss of E-cadherin has been causally associated to the transition
of adenoma to carcinoma and the acquisition of migration
capacity. As stated above, VDR is also lost at late stages of colon
cancer progression, impairing the induction of E-cadherin by
1,25(OH)2D3. Concordantly with these and our results, we propose
that SNAIL promotes the acquisition of invasive behaviour via the
repression of both VDR and E-cadherin genes. The repression of
VDR by SNAIL is particularly relevant due to the protective action
of 1,25(OH)2D3 and analogues on colon carcinogenesis, and
constitutes a second mechanism for the efficient repression of E-
cadherin. We have not found regulation of SNAIL RNA expression
in colon cancer cells by 1,25(OH)2D3. Subcellular localisation and
degradation of SNAIL protein is regulated by phosphorylation
(Zhou et al, 2004) but, likewise, 1,25(OH)2D3 does not change
SNAIL protein localisation in SW480-ADH cells.
During development, SNAIL expression is linked to cell
deadhesion and migration processes, but it is downregulated when
the cells have reached their destination. In human breast cancer
metastasis E-cadherin is re-expressed (Bukholm et al, 2000),
suggesting that SNAIL might be downregulated. Whether this
occurs in colon metastasis remains to be elucidated. Likewise, no
data are available on VDR expression in metastasis. The possibility
that SNAIL upregulation reported in melanoma, gastric or other
cancers may also cause VDR downregulation in these neoplasias
remains unexplored. The VDR gene is subjected to complex
transcriptional regulation: Wilm’s tumour suppressor, Zeb-1, Cdx-2
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VDR expression. At least during tumorigenesis, SNAIL seems to
overcome these factors.
Therapeutic implication of the repression of VDR by
SNAIL
Only a subset of cancer patients treated with vitamin D analogues
respond to therapy. As with other therapies, it is important to
select those patients that are likely to respond. An example is the
selection of breast cancer patients with high HER2/Neu expression
as candidates for treatment with anti-HER2/Neu antibodies. Our
data indicate that colon cancer patients with SNAIL upregulation
express low VDR and are thus likely to be poor responders to
vitamin D analogues. As SNAIL upregulation seems to be linked to
the acquisition of the migratory/invasive phenotype, which
correlates with the metastatic potential, patients with low-grade
colon cancers are preferential candidates for this therapy
(Figure 2). In cases of acceptable toxicities, they may also be
useful as chemopreventive agents for high-risk patients. Our
studies show that the balance between VDR and SNAIL expression
plays an important role in the control of cell fate during colon
cancer progression, and emphasise the need to analyse VDR and/
or SNAIL expression in colon cancers in order to select patients
suitable for therapy with vitamin D analogues. An attractive, albeit
unexplored, possibility is the study of SNAIL or VDR RNA levels in
blood, a strategy used for cytokeratin 19, carcinoembryonic
antigen and b-catenin in colorectal cancer (Silva et al, 2002) and
other genes in different neoplasias. If upregulation of SNAIL or
downregulation of VDR in tumours could be monitored by RT–
PCR analysis of circulating RNA levels, this would constitute a
valuable tool for the selection of candidates for therapy with
vitamin D analogues.
CONCLUSIONS
1,25(OH)2D3 has profound effects on gene expression, inducing
differentiation and inhibiting proliferation of colon cancer cells.
Preclinical and epidemiological data suggest that vitamin D
analogues may be useful for the prevention and treatment of
colorectal cancer. To date, however, therapy with these compounds
has benefited only a limited number of cancer patients. The SNAIL
transcription factor inhibits the expression of genes encoding
adhesive proteins and causes the acquisition of migratory and
invasive phenotype of epithelial cells, and is thus considered an
important factor of malignancy. Recent data have shown that
SNAIL represses VDR gene expression in cultured human colon
cancer cells, leading to hormone unresponsiveness in vitro and in
vivo. Since SNAIL is upregulated during human colon cancer
progression, which is associated with reduced VDR expression, the
analysis of SNAIL expression may help to select patients suitable
for therapy with vitamin D analogues.
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